Neoadjuvant therapy shows high efficacy in advanced gastric cancer

Neoadjuvant chemotherapy combining a PD-1 inhibitor, apatinib, S-1, and oxaliplatin demonstrates significant efficacy for locally advanced gastric cancer (LAGC). In a study involving 130 patients, clinical complete response was achieved in 4.6%, with a total response rate of 71.5%. Notably, 96.1% underwent R0 resection, while 21.6% attained pathological complete response. The treatment was deemed safe, with no severe adverse events reported, underscoring the potential of this approach in improving surgical outcomes.